Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.21% | 52.30% | -19.20% | -85.84% | -165.08% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -84.45% | 194.77% | -95.30% | -100.00% | 1,810.41% |
| Total Other Non-Cash Items | 66.03% | -83.52% | -28.70% | 1.26% | 7.49% |
| Change in Net Operating Assets | 330.52% | 19.49% | 85.54% | -667.60% | -166.97% |
| Cash from Operations | 68.27% | -87.86% | 30.83% | -1,425.00% | -1,048.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -187.89% | -552.95% | 599.56% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -67.66% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.59% | -116.54% | -590.81% | 599.56% | 3,294.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.40% | -1,107.47% | -1,846.19% | -4,199.40% | 56,620.00% |